Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bitwise Crypto Industry Innovators ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Bitwise Crypto Industry Innovators ETF trades at $23.75. The key difference: Bitwise Crypto Industry Innovators ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BITQ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $30.43 |
52-Week Low | $278.09 | $16.74 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BITQ is trading at $23.93, down 0.91% on the day, with technical indicators showing a bearish trend across moving averages and oscillators. The stock faces resistance at $24 and support at $23. Recent news highlights investor concerns about cryptocurrency exposure through ETFs, though some analysts see potential in crypto industry innovators during market recoveries.
The outlook remains cautious due to weak technical momentum and sector volatility. Investment opportunity exists for those betting on long-term crypto industry growth, but risks include regulatory uncertainty and market sentiment swings. Current levels near support may attract contrarian buyers if broader crypto markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
